Search results
Results from the WOW.Com Content Network
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. Shares of newly public AMRX began trading on the NYSE on May 7, 2018. [9] Concurrent with the Impax merger, Amneal acquired Gemini Laboratories for $117 million, including Unithroid, Gemini's lead product for treating hypothyroidism. [10]
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and ...
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and ...
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and ...
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and ...
Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR® HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (Nasdaq: IPXL) today announced that it has ...
Yesterday, the Food and Drug Administration handed Impax Laboratories a complete response letter, or CRL, for its experimental Parkinson's disease drug Rytary. While an FDA rejection can spell ...
Impax Pharmaceuticals Announces Extension of Rytary TM FDA Review Date to January 21, 2013 HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Pharmaceuticals,the branded products division of Impax ...